tiprankstipranks
Advertisement
Advertisement

ARMP Stock Latest News

Armata Pharmaceuticals price target raised to $20 from $15 at JonesResearch
The FlyArmata Pharmaceuticals price target raised to $20 from $15 at JonesResearch
1d ago
ARMP
Armata Pharmaceuticals Sets Timeline for 2026 Annual Meeting
PremiumCompany Announcements
Armata Pharmaceuticals Sets Timeline for 2026 Annual Meeting
7d ago
8K
ARMP
Armata Pharmaceuticals reports Q4 EPS ($3.42) vs. (23c) last year
PremiumThe Fly
Armata Pharmaceuticals reports Q4 EPS ($3.42) vs. (23c) last year
15d ago
ARMP
Armata Highlights AP-SA02 Progress Amid Earnings Release Delay
PremiumCompany Announcements
Armata Highlights AP-SA02 Progress Amid Earnings Release Delay
21d ago
8K
ARMP
Armata Pharmaceuticals delays announcement of Q4, FY25 results
PremiumThe Fly
Armata Pharmaceuticals delays announcement of Q4, FY25 results
21d ago
ARMP
ARMP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsARMP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
23d ago
ARMP
Armata price target raised to $15 from $9 at H.C. Wainwright
Premium
The Fly
Armata price target raised to $15 from $9 at H.C. Wainwright
1M ago
ARMP
Armata Gains QIDP Status for AP-SA02 Bacteremia Therapy
Premium
Company Announcements
Armata Gains QIDP Status for AP-SA02 Bacteremia Therapy
2M ago
8K
ARMP
Armata Pharmaceuticals receives FDA QIDP designation for AP-SA02
PremiumThe Fly
Armata Pharmaceuticals receives FDA QIDP designation for AP-SA02
2M ago
ARMP
Armata Extends Innoviva Credit, Warrants and Voting Pact
PremiumCompany Announcements
Armata Extends Innoviva Credit, Warrants and Voting Pact
2M ago
8K
ARMP
Armata Pharmaceuticals: FDA-Endorsed Phase 3 Path and Potential QIDP Upside Support Buy Rating on AP-SA02
PremiumRatings
Armata Pharmaceuticals: FDA-Endorsed Phase 3 Path and Potential QIDP Upside Support Buy Rating on AP-SA02
3M ago
ARMP
Armata Wins FDA Support to Advance Bacteriophage to Phase 3
PremiumCompany Announcements
Armata Wins FDA Support to Advance Bacteriophage to Phase 3
3M ago
8K
ARMP
Armata Pharmaceuticals announces End-of-Phase 2 meeting with FDA
PremiumThe FlyArmata Pharmaceuticals announces End-of-Phase 2 meeting with FDA
3M ago
ARMP
Armata Pharmaceuticals initiated with a Buy at JonesResearch
Premium
The Fly
Armata Pharmaceuticals initiated with a Buy at JonesResearch
3M ago
ARMP
Armata Pharmaceuticals Enters Capital Sales Agreement
Premium
Company Announcements
Armata Pharmaceuticals Enters Capital Sales Agreement
4M ago
8K
ARMP
Armata Pharmaceuticals: Strategic Advancements and Clinical Progress Drive Buy Rating
PremiumRatings
Armata Pharmaceuticals: Strategic Advancements and Clinical Progress Drive Buy Rating
5M ago
ARMP
Armata Pharmaceuticals reports Q3 EPS (74c) vs. (15c) last year
PremiumThe Fly
Armata Pharmaceuticals reports Q3 EPS (74c) vs. (15c) last year
5M ago
ARMP
Armata Pharmaceuticals: Strategic Advancements and Operational Milestones Justify Buy Rating
PremiumRatings
Armata Pharmaceuticals: Strategic Advancements and Operational Milestones Justify Buy Rating
5M ago
ARMP
Armata Pharmaceuticals trading resumes
PremiumThe Fly
Armata Pharmaceuticals trading resumes
5M ago
ARMP
Armata Pharmaceuticals trading halted, volatility trading pause
PremiumThe FlyArmata Pharmaceuticals trading halted, volatility trading pause
5M ago
ARMP
Armata announces comissioning of cGMP manufacturing facility in Los Angeles
Premium
The Fly
Armata announces comissioning of cGMP manufacturing facility in Los Angeles
5M ago
ARMP
ARMP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ARMP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
5M ago
ARMP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >